2022.07.18
I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022
I-Mab today announced that it will present the latest Phase 2 clinical data of lemzoparlimab in combination with azacitidine in patients with higher risk myelodysplastic syndrome as a proffered paper at 2022 ESMO Congress.